Biosortia Microbiomics

Biosortia Microbiomics is a private U.S. biotechnology company developing drug candidates and discovery assets from previously inaccessible natural microbiomes. The company positions itself as a microbiome-mining and natural-products platform business, using large-scale harvesting, analytics, and AI-enabled prioritization to identify novel microbial small molecules and associated datasets. In addition to platform licensing, Biosortia offers access to novel and rare known small-molecule libraries and collaborates with research and academic partners. Its disclosed therapeutic efforts are centered on orally available, microbiome-derived small molecules, including an obesity program and an enteric nervous system-focused CNS program. The company appears to be at a preclinical discovery stage overall, with a business model spanning internal therapeutics, data licensing, and external collaborations.